Company news

ProQR Therapeutics N.V. news in 2020

ProQR Therapeutics N.V.'s news releases, calls and decks from 2020, newest first.

View company

ProQR Announces Third Quarter 2020 Operating and Financial Results

November 15, 2020

ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO)

November 1, 2020

ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer

October 4, 2020

ProQR Announces Virtual Presentations at Scientific Conferences

September 23, 2020

ProQR Announces Second Quarter 2020 Operating and Financial Results

August 5, 2020

ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy

July 20, 2020

ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures

July 13, 2020

ProQR Announces Expert Perspectives Conference Call Series

June 11, 2020

ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)

June 7, 2020

ProQR Announces First Quarter 2020 Operating and Financial Results

May 6, 2020

ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update

March 30, 2020

ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome

March 24, 2020

ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update

February 25, 2020

ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a

January 29, 2020

Decks in 2020